These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23859540)

  • 1. Normalization of kidney dysfunction in normotensive, normo-albuminuric type 2 diabetes.
    Futrakul N; Futrakul P
    Ren Fail; 2013 Aug; 35(7):1058-9. PubMed ID: 23859540
    [No Abstract]   [Full Text] [Related]  

  • 2. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 3. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes.
    Ruggenenti P; Remuzzi G
    Exp Nephrol; 1996; 4 Suppl 1():53-60. PubMed ID: 9001898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic Kidney Disease.
    Tong L; Adler SG
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
    [No Abstract]   [Full Text] [Related]  

  • 7. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
    Nitschmann S; Girndt M; Köhler H
    Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
    [No Abstract]   [Full Text] [Related]  

  • 8. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 9. Renal protection in diabetes.
    Hunter JD; Ravert PK; Lassetter JH; Williams M
    Adv NPs PAs; 2011 Jan; 2(1):25-9; quiz 30. PubMed ID: 21329229
    [No Abstract]   [Full Text] [Related]  

  • 10. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 11. Addition of silymarin to renin-angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial.
    Voroneanu L; Siriopol D; Dumea R; Badarau S; Kanbay M; Afsar B; Gavrilovici C; Covic A
    Int Urol Nephrol; 2017 Dec; 49(12):2195-2204. PubMed ID: 28948420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotection with antihypertensive agents.
    Hilgers KF; Mann JF
    Lancet; 2002 May; 359(9318):1693; author reply 1693-4. PubMed ID: 12020551
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of suspending ACE inhibitors and ARBs in advanced chronic kidney disease.
    Díaz-Domínguez ME; Fernández-Lucas M; Gomis-Couto A; Ruiz-Roso G; Teruel JL; Quereda C
    Nefrologia; 2012 May; 32(3):400-1. PubMed ID: 22592428
    [No Abstract]   [Full Text] [Related]  

  • 14. ACE inhibitors or ARBs for diabetic nephropathy: the unrelenting debate.
    Kota SK; Meher LK; Jammula S; Kota SK; Modi KD
    Diabetes Metab Syndr; 2012; 6(4):215-7. PubMed ID: 23199543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.
    Afghahi H; Miftaraj M; Svensson AM; Hadimeri H; Gudbjörnsdottir S; Eliasson B; Svensson MK;
    J Diabetes Complications; 2013; 27(3):229-34. PubMed ID: 23246248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of endothelial dysfunction and early therapeutic correction effectively restore renal function in type 2 diabetic nephropathy.
    Futrakul N; Butthep P
    Ren Fail; 2005; 27(4):493-4. PubMed ID: 16060141
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment and physiopathology of diabetic nephropathies].
    Nakamoto Y; Inomata S
    Nihon Naika Gakkai Zasshi; 1990 Feb; 79(2):200-4. PubMed ID: 2193992
    [No Abstract]   [Full Text] [Related]  

  • 18. [Protective effect of angiotensin coverting enzyme inhibitor on renal function in normotensive non-insulin dependent diabetes mellitus patients with early diabetic nephropathy and microalbuminuria].
    Xia H; He R; Chen J
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):533-6. PubMed ID: 9594145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
    Zidek W
    MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
    [No Abstract]   [Full Text] [Related]  

  • 20. [Type 2 diabetes mellitus and chronic kidney disease].
    Ponťuch P
    Vnitr Lek; 2017; 63(3):188-192. PubMed ID: 28379021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.